BEKEMV®▼(eculizumab) PATIENT SAFETY CARD

▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects you can help provide more information on the safety of this medicine. Side effects can also be reported to Amgen Limited on +44 (0) 1223 436441.

Important Safety Information for Patients Receiving BEKEMV

Show this card to any doctor involved in your care.

BEKEMV can lower the ability of your immune system to fight infections. Serious infections including sepsis may develop, **especially meningococcal infection, which requires immediate medical attention.** If you experience any of the following symptoms, you should immediately call your doctor.

If you cannot reach your doctor, go to an Accident and Emergency department and show them this card.

- Headache with nausea or vomiting
- Headache with a stiff neck or stiff back
- Fever (raised temperature)
- Rash
- Confusion
- Muscle aches with flu-like symptoms
- Eyes sensitive to light

Seek emergency medical care immediately if you have any of these signs or symptoms and show this card.

Even if you stop using BEKEMV, keep this card with you for 3 months after your last BEKEMV dose. Your risk of meningococcal infection may continue for a long time after your last dose of BEKEMV.

This medicine contains 50 mg sorbitol (E420) in each mL. Intravenous administration of sorbitol could be life threatening for people with hereditary fructose intolerance (HFI). Babies and young children below 2 years of age may not yet be diagnosed with HFI. **BEKEMV must not be used in babies and young children below 2 years of age.**

PATIENT SAFETY CARD

Information for the Treating Doctor

This patient has been prescribed BEKEMV® (eculizumab), which increases the patient's susceptibility to meningococcal infection *(Neisseria meningitidis)* **and other general infections.**

- Meningococcal infections may become rapidly life-threatening or fatal if not recognised and treated early
- **Evaluate immediately if infection is suspected and treat with appropriate antibiotics if necessary**

- BEKEMV is contraindicated in babies and young children below 2 years of age. After intravenous administration of a sorbitol-containing medicine like BEKEMV, patients with HFI may present with hypoglycaemia, metabolic acidosis, seizures, coma, which could be life threatening. Evaluate immediately if HFI is suspected and treat appropriately.
- Contact prescribing doctor (below) as soon as possible

For more information about BEKEMV, please refer to the full Summary of Product Characteristics https://www.medicines.org.uk/emc or e-mail gbinfoline@amgen.com or telephone 01223 436441.

In case of safety concerns telephone 01223 436441.

Patients receiving BEKEMV should carry this card at all times

Patient name_____

Hospital where treated_____

Doctor's name_____

Tel. number_____

Vaccination date _____

AMGEN

BEKEMV®_AlertCard_V3; September 2024 Great Britain